Pricing Log in Create free account
Saturday 17 October 2026 Export MDXHF’s income statement to Excel — free account

MedX Health Corp.

MDXHF Healthcare Diagnostics & Research

MedX Health Corp.’s revenue for fiscal 2025 (year ended December 2025) was $338,700.00, down 5.23% from fiscal 2024. In the quarter to June 2026, revenue grew 33.6%, EPS fell 6.06%, free cash flow grew 41.6% and total debt fell 8.75%, each against the same quarter a year earlier.

0.03 0.00 0.00%
Market cap
$103.2M
P/E
0.0×
Fwd P/E
−7.3×
Dividend yield
—
F-score
2/9
Altman Z
−157.11
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 95.47%

Capital & Financial Ratios $m

Market Cap 103.16
Revenue 0.41
Net Income (4.43)
Free Cash Flow (2.71)
Net Debt 2.29
Current Ratio 0.02 (below 1: weak)
Debt/Equity (0.30) (negative: negative equity)
P/E ratio 0.00
Fwd P/E (7.32) (negative: loss-making)
P/S ratio 23.85 (above 10: high)
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth 54.50% (at or above 15%: strong)
Next Y EPS Growth 38.61% (at or above 15%: strong)
Next Y revenue growth 8.58%
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 29.4×, against a ten-year median of 0.4×; over the ten years it ranged from −1.1× in 2022 to 48.0× in 2025.
P/S against its own 10 years 90.01%
10-year low 10-year high
EV/Sales against its own 10 years 88.22%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 22 0 0 0
Receivables 11 0 0 0
Inventory 3 0 0 0
Other 2 — — —
38 1 0 0
2023 2024 2025 Q'26
Payables 9 2 2 2
ST’ Debt 1 1 1 1
Other 9 33 37 —
20 6 7 7

Compound Annual Growth %

10y 5y 3y
Sales — (55.05%) (79.09%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 0 0 0 0 0
’24 0 0 0 0 0
’23 15 17 19 19 70
’22 6 7 11 13 37
’21 — 11 5 11 22
’20 — 10 — 9 18
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (1) — — —
’25 0 (1) (1) (1) (3)
’24 0 (1) (1) 0 (2)
’23 (4) (6) (4) (7) (21)
’22 (9) (6) (9) (10) (34)
’21 — (12) (17) (6) (23)
’20 — (12) — (20) (20)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (1) — — —
’25 (1) (1) (1) (1) (3)
’24 (1) (1) (1) (1) (3)
’23 (5) (7) (5) (8) (24)
’22 (9) (7) (10) (11) (37)
’21 — (12) (18) (6) (23)
’20 — (12) — (21) (21)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.00 0.00 — — —
’25 0.00 0.00 0.00 0.00 (0.02)
’24 0.00 0.00 0.00 0.00 (0.01)
’23 (0.05) (0.30) (0.40) (0.39) (1.66)
’22 (0.05) (0.70) (0.05) (1.10) (2.80)
’21 — (0.11) — (0.10) (0.24)
’20 — (0.16) — (0.17) (4.25)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 0.05 0.08 0.10 0.07 0.04 0.04 0.02 0.02 0.00 0.00

Analyst estimates 2026–2028

Powerpack
High 0.19 0.15 0.21 0.12 0.12 0.19 0.06 0.06 0.06 0.05
People
People Employees — — — — — — — — — —
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Income, $m
Income, $m Revenue 29 43 33 13 18 22 37 70 0 0
Gross margin, % 60.76 69.40 48.62 (28.77) 43.58 47.50 51.87 62.58 39.65 (11.51)
EBT (13) (13) (37) (49) (29) (29) (44) (43) (3) (5)
EBT margin, % (44.33) (30.61) (114.42) (370.60) (155.27) (130.41) (118.86) (61.40) (745.91) (1,329.23)
Net income (13) 0 (37) (48) (27) (27) (38) (27) (3) (5)
Depreciation 2 2 3 4 3 3 5 7 0 0
Per share, $
Per share, $ Revenue 0.62 0.87 5.67 2.12 2.22 0.18 2.36 2.70 0.00 0.00
Earnings (0.27) (0.27) (6.47) (7.74) (4.25) (0.24) (2.80) (1.66) (0.01) (0.02)
Cash flow (0.34) (0.22) (5.77) (4.06) (2.43) (0.19) (2.17) (0.83) (0.01) (0.01)
Capex 0.00 0.00 0.00 0.00 (0.06) (0.01) (0.18) (0.11) 0.00 0.00
Free cash flow (0.34) (0.22) (5.77) (4.06) (2.50) (0.19) (2.35) (0.93) (0.01) (0.01)
Book value 1.14 0.88 10.40 3.54 0.70 0.39 0.59 0.28 (0.02) (0.02)
Shares, m 46 50 6 6 8 121 16 26 267 296
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 0.00 0.00 0.00 0.00 0.26 0.26 0.01 0.02 0.00 8.75
P/B 0.17 0.17 0.17 0.23 1.40 0.20 0.03 0.15 0.00 0.00
EV/Sales 0.00 0.00 0.00 0.00 0.24 (0.95) 0.63 0.26 5.93 12.29
EV/FCF 0.00 0.00 0.00 0.00 (0.13) 0.63 (0.60) (0.62) (0.47) (0.79)
Cash, $m
Cash, $m Operating cash flow (16) (11) (33) (25) (20) (23) (34) (21) (2) (3)
Capex (5) (5) (2) 0 (1) (1) (3) (3) (1) 0
Free cash flow (16) (11) (33) (25) (21) (23) (37) (24) (3) (3)
Balance, $m
Balance, $m Working capital 39 26 42 23 10 50 11 19 (5) (7)
Total debt 1 1 1 12 15 15 39 40 2 1
Net debt (30) (16) (30) (12) (1) (44) 23 17 2 1
Shareholders’ equity 53 44 60 22 6 47 9 7 (6) (7)
Returns, %
Returns, % ROA (19.85) (38.84) (52.22) (80.10) (73.96) (54.25) (45.36) (34.72) (4.11) (784.34)
ROIC 0.00 0.00 0.00 0.00 (338.36) (538.20) (77.00) (69.39) 0.00 0.00
ROE (26.03) (27.25) (72.01) (118.02) (204.65) (109.96) (156.70) (521.70) (540.15) 68.26
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 2 Oct 2026

Charts ten years each

MedX Health Corp. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
BDSX Biodesix, Inc. $260.7M — (loss-making) — (loss-making) +34.18% (above 0%: growing) n/m +72.75% (above 0%: growing) 82.06% (20.06%) Compare
XGN Exagen Inc. $207.4M — (loss-making) — (loss-making) +15.92% (above 0%: growing) n/m +211.34% (above 0%: growing) 61.27% (8.64%) Compare
BNR Burning Rock Biotech Limited Sponsored ADR $137.1M — (loss-making) 11.1× −4.22% (below 0%: shrinking) n/m +46.01% (above 0%: growing) 72.58% (13.36%) Compare
MDXHF MedX Health Corp. $103.2M — (loss-making) — (loss-making) +33.59% (above 0%: growing) n/m +41.60% (above 0%: growing) 37.19% (1,027.95%)
IMDX Insight Molecular Diagnostics Inc. $100.1M — (loss-making) — (loss-making) −53.86% (below 0%: shrinking) n/m −54.02% (below 0%: shrinking) 65.69% (4,770.71%) Compare
QUCY Quantum Cyber N.V $95.1M — (loss-making) — (loss-making) +11.12% (above 0%: growing) n/m +26.73% (above 0%: growing) 62.71% 0.00% Compare
MDXH MDxHealth SA $57.6M — (loss-making) — (loss-making) +12.01% (above 0%: growing) n/m −200.20% (below 0%: shrinking) 65.75% (18.74%) Compare
MBAI MBody AI Ltd. $47.4M — (loss-making) — — n/m +122.08% (above 0%: growing) 0.00% 0.00% Compare
PRPO Precipio, Inc. $40.4M — (loss-making) 15.4× +24.18% (above 0%: growing) n/m +79.59% (above 0%: growing) 44.67% (8.53%) Compare
Median of peers $97.6M — — +12.01% — +59.38% 64.20% (11.00%)

All 52 Diagnostics & Research stocks →

MedX Health Corp. (MDXHF) key facts

  • Concern: MedX Health Corp.’s revenue for fiscal 2025 (year ended December 2025) was $338,700.00, down 5.23% from fiscal 2024.
  • MedX Health Corp. (MDXHF) is a Diagnostics & Research company in the Healthcare sector.
  • As of October 14, 2026, MDXHF traded at $0.03, a market capitalization of $103.2 million.
  • Return on equity was 68.3% and debt-to-equity -0.30.
  • Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −157.11 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 2, 2026.

MedX Health Corp. (MDXHF) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/MDXHF · Data as of Oct 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com